Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of subcutaneous efgartigimod PH20 in adults with primary Sjogren's disease
jRCT2031240584Phase 3Active, not recruiting
- Sponsor
- argenx
- Start
- Dec 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of efgartigimod alfa + hyaluronidase-qvfc in primary Sjögren's syndrome (3 arms), sponsored by argenx. Primary endpoint: Change from baseline in clinESSDAI at week 48. Started Dec 2024; status: active, not recruiting.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on jRCT2031240584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240584.